Insmed (NASDAQ:INSM) Releases Quarterly Earnings Results

Insmed (NASDAQ:INSM - Get Free Report) announced its earnings results on Thursday. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15), Zacks reports. The company had revenue of $104.44 million during the quarter, compared to the consensus estimate of $102.31 million. Insmed updated its FY 2025 guidance to EPS.

Insmed Price Performance

Shares of INSM stock traded down $2.55 during trading hours on Friday, hitting $81.06. The stock had a trading volume of 2,722,240 shares, compared to its average volume of 1,948,698. Insmed has a one year low of $21.92 and a one year high of $84.91. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The stock's 50-day moving average price is $74.29 and its two-hundred day moving average price is $73.59. The stock has a market capitalization of $14.50 billion, a price-to-earnings ratio of -14.61 and a beta of 1.11.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on INSM shares. Morgan Stanley raised their target price on Insmed from $85.00 to $90.00 and gave the stock an "overweight" rating in a report on Thursday, February 6th. JPMorgan Chase & Co. raised their target price on Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a report on Friday, February 7th. Stifel Nicolaus decreased their target price on Insmed from $97.00 to $96.00 and set a "buy" rating on the stock in a report on Friday. Guggenheim raised their target price on Insmed from $95.00 to $101.00 and gave the stock a "buy" rating in a report on Friday, February 7th. Finally, Wells Fargo & Company raised their target price on Insmed from $85.00 to $107.00 and gave the stock an "overweight" rating in a report on Wednesday. One investment analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company's stock. According to MarketBeat.com, Insmed presently has a consensus rating of "Moderate Buy" and an average price target of $91.00.

Insider Transactions at Insmed

In related news, insider Martina M.D. Flammer sold 6,172 shares of Insmed stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $63.64, for a total value of $392,786.08. Following the completion of the transaction, the insider now owns 101,549 shares in the company, valued at approximately $6,462,578.36. This trade represents a 5.73 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO William Lewis sold 18,750 shares of Insmed stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $69.91, for a total value of $1,310,812.50. Following the completion of the transaction, the chief executive officer now owns 384,960 shares of the company's stock, valued at approximately $26,912,553.60. This represents a 4.64 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 532,207 shares of company stock valued at $41,400,465. 4.60% of the stock is currently owned by insiders.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.